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Abstract
A large percentage of breast cancer heritability remains unaccounted for, and most of the known susceptibility loci have 
been established in European and Asian populations. Rare variants may contribute to the unexplained heritability of this 
disease, including in women of African ancestry (AA). We conducted an exome-wide analysis of rare variants in relation to 
risk of overall and subtype-specific breast cancer in the African American Breast Cancer Epidemiology and Risk (AMBER) 
Consortium, which includes data from four large studies of AA women. Genotyping on the Illumina Human Exome 
Beadchip yielded data for 170 812 SNPs and 8287 subjects: 3629 cases (1093 estrogen receptor negative (ER−), 1968 ER+, 568 
ER unknown) and 4658 controls, the largest exome chip study to date for AA breast cancer. Pooled gene-based association 
analyses were performed using the unified optimal sequence kernel association test (SKAT-O) for variants with minor 
allele frequency (MAF) ≤ 5%. In addition, each variant with MAF >0.5% was tested for association using logistic regression. 
There were no significant associations with overall breast cancer. However, a novel gene, FBXL22 (P = 8.2 × 10–6), and a 
gene previously identified in GWAS of European ancestry populations, PDE4D (P = 1.2 × 10–6), were significantly associated 
with ER− breast cancer after correction for multiple testing. Cases with the associated rare variants were also negative 
for progesterone and human epidermal growth factor receptors—thus, triple-negative cancer. Replication is required to 
confirm these gene-level associations, which are based on very small counts at extremely rare SNPs.
Introduction
Genome-wide association studies (GWAS) have identified more 
than 90 genetic loci associated with breast cancer (1,2). Per-
allele odds ratios have been modest (most <1.2), as is typical 
for GWAS findings. These low-penetrance loci, together with 
previously discovered high- and moderate-penetrance genes, 
fail to explain the majority of the genetic contribution to the 
disease (1–4). Most GWAS-based associations have been estab-
lished in European or Asian populations, and the majority of 
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these associations have failed to reach statistical significance in 
studies of African ancestry (AA) women (5–15). While larger AA 
sample sizes and an accounting for differences in linkage dis-
equilibrium across ethnicities would likely result in more suc-
cessful replications, the European-discovered risk variants may 
also explain less of the genetic contribution to breast cancer in 
AA women.
While some of the unexplained breast cancer heritability in 
AA women is surely due to unidentified common susceptibil-
ity SNPs in this population, another portion may be explained 
by less common (1–5%) and rare variants (< 1%). These lower 
frequency variants represent a large proportion of all human 
genetic variation but are poorly captured by most GWAS arrays 
(16). There are a growing number of examples of rare variants 
associated with complex disease, with findings for autism, 
schizophrenia, inflammatory bowel disease and diabetes (17). In 
addition to the already established high- and moderate-pene-
trance genes for breast cancer (3,4,18), novel low frequency risk 
variants for cancers including prostate (19) and ovarian (20,21) 
have also been reported. Still, it remains unclear how much rare 
variants contribute to the heritability of breast cancer and other 
complex diseases.
In recent years, the development of exome-wide arrays has 
allowed for the relatively inexpensive assessment of known 
rare exonic variants. Current exome arrays include >200 000 
coding variants and were developed on the basis of whole 
exome sequencing data from ~12 000 individuals. Most of those 
sequenced were of European ancestry, but a small number of 
AAs and other ethnicities were included as well (16,22).
A case-control study nested in the Multiethnic Cohort (MEC) 
used the Illumina exome chip to investigate the role of rare 
exonic variation in the etiology of breast cancer (16). Single 
SNP analyses were conducted, as well as gene-based testing of 
the burden of rare alleles. Only one significant association was 
found, for splice-site SNP rs145889899 in the LDLRAD1 gene. This 
variant was only seen in AAs (with a frequency of 0.65% in AA 
controls) and had an odds ratio of 3.74. While no additional find-
ings were significant, there was low power to detect genotype 
relative risks ≤ 2 in the AA participants due to the modest num-
ber of available AA cases (N = 591).
The present study combined the MEC exome chip data with 
exome chip data from three additional studies of breast can-
cer in AA women, forming the African American Breast Cancer 
Epidemiology and Risk (AMBER) Consortium, the largest exome 
wide analysis sample to date for AA breast cancer (3629 cases 
and 4658 controls). We primarily used gene-based methods for 
association analysis, given the relatively low power and high 
multiple testing burden for single SNP analyses of rare variants 
(22,23). Gene-based testing has the potential to increase power 
when multiple SNPs in a given gene are associated (22).
Materials and methods
Study population
This investigation was conducted using data from the AMBER Consortium, 
a collaboration of four of the largest studies of breast cancer in AA women. 
The AMBER Consortium has been described previously (24), and prior 
reports have detailed the individual studies: the Carolina Breast Cancer 
Study (CBCS) (25), the Women’s Circle of Health Study (WCHS) (26,27), the 
Black Women’s Health Study (BWHS) (28), and the Multiethnic Cohort 
(MEC) (29). Institutional Review Board approval was obtained for each 
study, and all participants provided written informed consent.
Briefly, the CBCS is a North Carolina population-based case-control 
study of women aged 20–74 years that began in 1993. The North Carolina 
Central Cancer Registry’s rapid case ascertainment system was used 
for case identification, and controls were selected through 2001 using 
Division of Motor Vehicles lists (age < 65 years) and Health Care Financing 
Administration lists (age ≥ 65). Interviewers collected questionnaire data 
and samples for DNA analysis in home visits.
The WCHS is a multi-site case-control study in New York City (NYC) 
(2002–2008) and New Jersey (NJ) (2006-present). Hospital-based ascer-
tainment of cases aged 20–75 years was used in NYC, and controls were 
selected through random digit dialing. Cases in NJ are identified by the NJ 
State Cancer Registry using rapid case ascertainment, and controls are 
identified through random digit dialing and community-based efforts (27). 
Risk factor data and samples for DNA analysis are obtained during in-
person interviews.
The BWHS is a prospective cohort study of 59 000 AA women from 
across the United States who enrolled by completing a postal health ques-
tionnaire in 1995. The age range at baseline was 21–69  years. Biennial 
follow-up questionnaires identify new cases of breast cancer, and these 
cases are confirmed by medical records or from state cancer registry data 
and the National Death Index. Nearly 27 000 BWHS participants provided 
saliva samples for DNA analysis.
The MEC is a prospective cohort study that began in 1993 with the 
enrollment of men and women aged 45–75 years from a range of ethnic 
groups in Hawaii and California. Data are collected by mailed question-
naire at 5-year intervals, and breast cancer cases are confirmed through 
the Hawaii and California state cancer registries and the National Death 
Index. Blood samples were collected from study participants for DNA 
analysis.
Eligible cases for the present analyses were AA women with incident 
invasive breast cancer or ductal carcinoma in situ (DCIS). For BWHS and 
MEC, controls were chosen from among women without breast cancer, 
and were frequency matched to cases on geographical region, sex, race 
and 5-year age group. ER status for cases was determined using pathology 
data from hospital records or cancer registry records.
Genotyping and QC
Genotyping of DNA from participants in the BWHS, CBCS and WCHS was 
performed by the Center for Inherited Disease Research (CIDR) using 
the Illumina Human Exome Beadchip v1.1. This array includes >200 000 
coding variants, as well as tag SNPs for GWAS hits, a grid of common 
variants, and ancestry informative markers (AIMs). A description of the 
exome chip design is available from http://genome.sph.umich.edu/wiki/
Exome_Chip_Design. CIDR used the GenTrain Version 1.0 calling algorithm 
in GenomeStudio version 2011.1, Genotyping Module 1.9.4. Manual review 
was conducted for all Y, XY pseudoautosomal and mitochondrial SNPs. 
Autosomal and X chromosome SNPs were also manually reviewed if a rare 
heterozygous cluster may have been missed by the GenCall algorithm and 
if the zCall algorithm (30) identified four or more possible new heterozy-
gous points.
A total of 246 519 SNPs were genotyped, and 231 705 SNPs remained 
after excluding variants that failed technical filters imposed by CIDR, or QC 
filters recommended by the University of Washington. Briefly, genotypes 
with a GenCall (GC) score <0.15 were classified as missing, and SNPs were 
removed if they had poor cluster properties (ex. cluster separation <0.2 
or <0.3 depending on allele frequency), call rates <0.98, Hardy–Weinberg 
Equilibrium P < 1 × 10-4, >1 Mendelian error in trios from HapMap (31) or >2 
discordant calls in duplicate samples. Mitochondrial and Y chromosome 
SNPs were also removed. Genotypes were attempted for 6936 participants 
from the BWHS, CBCS and WCHS, and were completed with call rate >98% 
for 6828 participants, which included 3130 cases (963 estrogen receptor 
negative (ER−), 1674 ER+, 493 ER unknown) and 3698 controls.
Genetic data from 499 cases (130 ER−, 294 ER+, 75 ER unknown) and 960 
controls in the MEC were available from genotyping on a previous version 
of the exome chip (16) which contained >99% of the high quality variants 
from v1.1. Genotypes from MEC were combined with the data from the 
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other AMBER studies into a data set containing 245 571 SNPs. Greater than 
66 000 SNPs were monomorphic in the combined set and were omitted 
from analyses, as were SNPs with high quality data from only one of the 
two exome chips and SNPs with any discordant genotypes across the two 
chips for 30 MEC participants who were included on both. The final data 
set for analysis included 170 812 SNPs and 8287 participants: 3629 cases 
(1093 ER−, 1968 ER+, 568 ER unknown) and 4658 controls.
We used the CHARGE (Cohorts for Heart and Aging Research in 
Genomic Epidemiology) Consortium’s annotation of exome chip variants 
(version 6, 11/7/14) downloaded from http://www.chargeconsortium.com/
main/exomechip (32). This annotation was performed with dbNSFP ver-
sion 2.6 (33,34).
We used the smartpca program in the EIGENSOFT package (35) to 
conduct a principal components analysis (PCA) based on ~42 000 com-
mon SNPs, most of which were custom content additions to the exome 
chip for use in other AMBER projects. In a separate analysis, PLINK version 
1.07 (36) was used to estimate identity by descent in participant pairs, and 
identified 130 sets of relatives across and within the individual studies, 
consisting of 270 individuals. These 270 individuals were flagged, as were 
35 outlying individuals from the PCA, so that sensitivity analyses could 
be performed. Genotype principal components were tested for associa-
tion with case status after controlling for the study covariates: study, DNA 
source (blood, saliva[Oragene], saliva[mouthwash]), and the matching 
variables. While no principal components were strongly associated in the 
multivariable model, we included terms for principal components with 
P < 0.1 in our analyses.
Association analysis
Gene-based association analyses for overall, ER+, and ER− breast cancer 
were conducted using the unified optimal sequence kernel association 
test (SKAT-O) (37), as implemented in the R package seqMeta (38). As a 
linear combination of the burden and SKAT (39) tests, SKAT-O achieves 
robust power whether a given gene has a high proportion of causal vari-
ants exerting effects in the same direction, or instead has many noncausal 
variants or variants exerting effects in opposite directions (22). We used 
the default SKAT-O option in the seqMeta package that considers rho = 1 
(burden) and rho = 0 (SKAT) tests and selects the optimal of the two tests. 
Depending on which test is chosen, SKAT-O models the phenotype versus 
a weighted aggregation of either the variants (burden test) or the variant 
score test statistics (SKAT) to produce a gene-level P value that indicates 
the degree of enrichment of rare variant associations in that gene (37). 
We included variants with minor allele frequency (MAF) ≤ 5%, and used 
the beta distribution weights proposed by Wu et al. (39), which upweight 
rarer variants, for both tests. We used a Bonferroni correction based on the 
number of genes evaluated to assess the significance of the gene-based 
test results.
We performed separate gene-based analyses for three successively 
less stringent sets of exonic variants: (1) ‘NS_strict’ variants (based on 
Purcell et al. (40)): stopgain, stoploss, frameshift or predicted damaging by 
all five of the following algorithms: SIFT (41), mutationTaster category [A 
or D] (42), LRT (43), PolyPhen_HDIV (44) and PolyPhen_HVAR (44), (2) ‘NS_
broad’ variants (Purcell et al. (40)): ‘NS_strict’ variants plus those variants 
that are predicted damaging by at least one of the five algorithms and (3) 
All nonsynonymous variants (‘NS_all’): ‘NS_broad’ variants plus all other 
missense and splice variants. Testing of these three sets of variants gave 
us more flexibility to find the best set of SNPs for gene-based analysis 
(ideally a set including most or all truly associated SNPs, but few, if any, 
unassociated SNPs).
Single SNP association analyses were conducted using logistic regres-
sion as implemented in PLINK version 1.07. These analyses were restricted 
to variants with MAF > 0.5% in order to avoid performing a large number 
of underpowered tests. We used a Bonferroni adjustment for the effective 
number of independent tests, applying the method of Gao et al. (45), to 
assess the significance of the single SNP results.
Both gene-based and single SNP analyses were adjusted for study, age, 
geographic region, DNA source and genotype principal components 5, 6 
and 8 in a pooled analysis that combined individual level data across the 
four studies in AMBER. This approach was preferred over meta-analysis 
given prior evidence that pooled analysis is more powerful for gene-based 
testing of rare variants under conditions where pooling is appropriate (46).
Results
The present analyses included 3629 breast cancer cases (1093 
ER−, 1968 ER+, 568 ER unknown) and 4658 controls. Table  1 
shows the distribution of ER subtypes and age at diagnosis for 
the cases by study site.
There were 184 100 annotation records for the 170 812 SNPs 
that passed QC filters: some SNPs mapped to more than one 
gene, and these multiple mappings were maintained for the 
gene-based analyses we performed. More than 80% of the SNP 
records were annotated as nonsynonymous, including mis-
sense, stopgain, stoploss, frameshift and splicing variants (see 
Supplementary Table  1, available at Carcinogenesis Online, for 
the full distribution of roles for the final SNP set). Over 80% of 
the SNPs had MAF <5% in AMBER, over 70% had MAF <1%, and 
nearly half of the SNPs had MAF <0.1%. QQ plots for the gene-
based and single SNP association analyses we performed are 
shown in Supplementary Figure  1, available at Carcinogenesis 
Online. As is common for SKAT analyses of binary traits, there 
was inflation in the gene-based tests (47,48).
The number of gene-based tests conducted and the result-
ing alpha levels for significance are listed in Table 2 by outcome 
and SNP group. As the SNP functional group became more strict, 
fewer tests were conducted because fewer genes contained at 
least two SNPs in the given group. Fewer gene-based tests were 
conducted for the ER+ and ER− analyses compared to overall 
breast cancer because these subtype analyses had smaller sam-
ple sizes, which resulted in more monomorphic SNPs that were 
excluded.
Table 3 shows the five most significant genes for each SKAT-O 
run (see Supplementary Table  2, available at Carcinogenesis 
Online, for the top 50 genes for each set of variants). For over-
all and ER+ breast cancer, RTN4RL1 was the most significant 
gene for both the ‘NS_all’ and ‘NS_broad’ SNP sets, with nomi-
nal P values ranging from 1.8 × 10–5 to 1.9 × 10–4. These results 
were based on 6–10 SNPs that were used in burden tests (the 
SKAT-O method selected rho = 1 as optimal in these instances). 
For the ‘NS_strict’ variants, the most significant genes for over-
all and ER+ breast cancer were IQCA1 (P = 4.6 × 10–4) and FSCN3 
(P = 2.3 × 10–4), respectively. None of the top results for overall or 
ER+ breast cancer survived a multiple testing correction based 
on the number of genes evaluated.
The most significant genes for ER− breast cancer were PDE4D 
(P = 1.2 × 10–6 using either the ‘NS_all’ or ‘NS_broad’ SNP sets) and 
FBXL22 (P  =  8.2 × 10–6 using the ‘NS_strict’ SNP set), and these 
Table 1. Characteristics of participants in the AMBER Consortium by 
study site
BWHS CBCS WCHS MEC ALL AMBER
Controls 2249 615 834 960 4658
Cases 901 1408 821 499 3629
 ER+ 498 741 435 294 1968
 ER− 233 565 165 130 1093
 ER unknown 170 102 221 75 568
Age at diagnosis
 <40 47 204 85 0 336
 40–49 262 459 215 9 945
 50–59 302 381 292 108 1083
 60–69 204 267 173 165 809
 ≥70 86 97 56 217 456
AMBER, African American Breast Cancer Epidemiology and Risk; BWHS, Black 
Women’s Health Study; CBCS, Carolina Breast Cancer Study; ER, estrogen recep-
tor; MEC, Multi-Ethnic Cohort; WCHS, Women’s Circle of Health Study.
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survived a correction for multiple testing. The PDE4D and FBXL22 
results were each based on burden testing (rho = 1) of two SNPs 
with a cumulative MAF ~0.02%. Details of the four SNPs con-
tributing to these significant test results are shown in Table 4. 
All of the contributing SNPs are nonsynonymous coding SNPs 
for multiple isoforms of PDE4D or FBXL22. These SNPs had good 
genotyping cluster properties (Supplementary Figure  2, avail-
able at Carcinogenesis Online) and 100% genotyping pass rates in 
the present study. Each SNP had an MAF ~0.01% in the AMBER 
analysis of ER− cases and controls, due to the presence of one 
rare allele in one invasive ER− case. The rare allele carriers were 
four independent participants (one for each SNP) with varying 
ages at diagnosis and percentages of AA (Table  4). All four of 
these women had triple-negative breast cancer (tumors nega-
tive for estrogen receptors, progesterone receptors and human 
epidermal growth factor receptor 2). Among all 1093 ER− cases, 
599 had been classified as triple negative based on available data 
on all three molecular markers. The four SNPs of interest are 
monomorphic in AAs from the 1000 Genomes Project (49) Phase 
3 and the NHLBI ESP (National Heart, Lung, and Blood Institute 
Exome Sequencing Project) (50). These same projects report very 
low allele frequencies (≤0.2%) for these SNPs in European ances-
try populations (Table 4).
Sensitivity analyses were run for the PDE4D and FBXL22 
genes versus ER− breast cancer, excluding first-degree and sec-
ond-degree relatives identified via the genotypes, as well as PCA 
outliers who clustered with HapMap 3 Europeans, Mexicans, or 
Asians. Results became more significant with these exclusions 
(PDE4D P = 9.9 × 10–7; FBXL22 P = 7.4 × 10–6).
Single SNP association analyses were performed for the 58 
776 SNPs with MAF >0.5%. The correlation among these SNPs 
yielded the equivalent of 50 245 independent tests (45); there-
fore, the threshold for significance was set at 9.95 × 10–7. SNP 
rs8100241, a previously reported risk marker at the ER−/ triple-
negative GWAS locus on chromosome 19p13.11 (12,52–56), met 
this study-wide threshold for ER− disease (P  =  1.7 × 10–7). The 
A allele at rs8100241 had a frequency of 40% in the present study 
and was associated with a decreased risk of ER− breast cancer 
(OR 0.75, 95% CI 0.68, 0.84). No other individual SNPs reached 
statistical significance (Supplementary Table  3, available at 
Carcinogenesis Online), including the LDLRAD1 SNP rs145889899 
(P = 0.17), for which an association had been reported in the MEC 
exome chip study (16).
Discussion
In these analyses, we observed significant associations between 
the PDE4D and FBXL22 genes and ER− breast cancer in a rela-
tively large sample of AA women, using gene-based testing of 
rare exonic variants. Two nonsynonymous coding SNPs in each 
of these genes were responsible for their significant associations. 
The minor allele at each of these four SNPs was present in one 
invasive ER− case each (a different case subject for each of the 
four SNPs). These four cases were all triple-negative breast can-
cers. The four SNPs of interest from these two genes were absent 
in the AMBER controls. This is consistent with their reported 
monomorphism in AA samples from the 1000 Genomes Project 
and the NHLBI ESP.
Although the association we report for the PDE4D gene is 
with ER− (and triple-negative) breast cancer, one of the two rare 
SNPs contributing to this association (rs201360779) was also 
seen in one invasive ER+ case. Thus, this gene may affect the 
risk of both ER subtypes. The two contributing PDE4D SNPs in 
our study were predicted to be damaging by mutationTaster 
(42), although SIFT (41) predicted that these mutations would be 
tolerated. The PolyPhen HDIV and HVAR models (44) predicted 
damaging results from rs200725508, but these algorithms pre-
dicted benign results for rs201360779 (with the exception of 
the HDIV prediction of ‘possibly damaging’ for this SNP for one 
PDE4D isoform).
The 2013 GWAS meta-analysis by Michailidou and colleagues 
(1) reported a breast cancer association with SNP rs1353747, 
which is located in an intron of PDE4D. In that study, the G allele 
at this common SNP showed weak protective associations for 
both ER+ and ER− disease. In this study, rs1353747 was not asso-
ciated with either disease subtype.
PDE4D is located on chromosome 5q11.2–12.1 and encodes 
phosphodiesterase subtype 4D, a member of the PDE4 family of 
phosphodiesterases, which multiple tumor cell types express 
as major regulators of cAMP degradation (57). PDE4D may func-
tion as a tumor-promoting factor by causing lower cAMP con-
centrations, which have been linked to increased survival and 
proliferation of cancer cells. This oncogenic role is supported by 
experiments showing that inhibition of PDE4D causes apoptosis 
and growth retardation in multiple types of cancer cells, includ-
ing breast, but not in nonmalignant epithelial cells (57).
Lin et al. (57) reported PDE4D homozygous deletions in 198 
of 5569 (3.6%) primary tumors from The Cancer Genome Atlas 
(TCGA) projects and TumorScape (58), with most being internal 
microdeletions. They also found microdeletions in established 
cancer cell lines including breast. These microdeletions were 
associated with increased expression of the protein, and they 
affected upstream conserved regions 1 (UCR1) and 2 (UCR2) of 
the gene. UCR1 and UCR2 inhibit PDE4D activity, likely by form-
ing complexes with the PDE4D catalytic domain before cAMP 
enters the site. Lin et al. showed that a short isoform of PDE4D 
with no functional UCR1 or UCR2 promoted cancer cell growth, 
while a long isoform that contained both UCR1 and UCR2 did 
not. In the present study, the two rare missense mutations 
contributing to the PDE4D gene-level association were located 
upstream of UCR1 and UCR2 and were risk variants (not protec-
tive). It could be hypothesized that these variants act by induc-
ing a change in protein structure that disrupts the interaction of 
the UCRs with the catalytic domain of PDE4D, thereby increasing 
protein activity.
Table 2. Number of gene-based tests conducted and corresponding 
significance criteria
Analysis
Number of genes 
tested
Alpha level for  
significance
Overall breast cancer
 ‘NS_all’ SNPsa 14 652 3.4 × 10–6
 ‘NS_broad’ SNPsb 12 515 4.0 × 10–6
 ‘NS_strict’ SNPsc 3128 1.6 × 10–5
ER+ breast cancer
 ‘NS_all’ SNPs 14 515 3.4 × 10–6
 ‘NS_broad’ SNPs 12 316 4.1 × 10–6
 ‘NS_strict’ SNPs 2963 1.7 × 10–5
ER− breast cancer
 ‘NS_all’ SNPs 14 399 3.5 × 10–6
 ‘NS_broad’ SNPs 12 184 4.1 × 10–6
 ‘NS_strict’ SNPs 2865 1.8 × 10–5
a‘NS_all’ SNPs: stopgain, stoploss, frameshift, missense or splicing.
b‘NS_broad’ SNPs: stopgain, stoploss, frameshift, or predicted damaging by at 
least one of the following algorithms: SIFT, mutationTaster category [A or D], 
LRT, PolyPhen_HDIV or PolyPhen_HVAR.
c‘NS_strict’ SNPs: stopgain, stoploss, frameshift or predicted damaging by all 
five algorithms.
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FBXL22 has not previously been associated with breast can-
cer. This gene is located on chromosome 15q22.31 and encodes 
F-box and leucine-rich repeat protein 22. This F-box protein, a 
ubiquitin ligase component, has been shown to promote the 
degradation of sarcomeric proteins, and is critical for main-
taining cardiac contractility in vivo (59). It is unclear what 
biological mechanism might link FBXL22 to breast cancer devel-
opment. Nevertheless, the two rare SNPs contributing to the 
Table 3. The most significant gene-based test results for each analysis
Gene Nominal P value Corrected P valuea rhob Cumulative MAF (%)
Number of SNPs  
included in the test
Overall breast cancer, ‘NS_all’ SNPs
 RTN4RL1 1.3 × 10–4 1 1 4.31 10
 TPCN1 2.0 × 10–4 1 0 0.32 9
 RARA 2.3 × 10–4 1 1 2.42 2
 KIF3C 3.0 × 10–4 1 1 2.62 6
 OBSCN 4.4 × 10–4 1 0 75.88 146
Overall breast cancer, ‘NS_broad’ SNPs
 RTN4RL1 1.9 × 10–4 1 1 1.96 6
 RARA 2.3 × 10–4 1 1 2.42 2
 GPRASP1 3.0 × 10–4 1 0 5.35 5
 NCAPG2 3.3 × 10–4 1 0 2.91 9
 TMEM130 3.6 × 10–4 1 0 0.11 2
Overall breast cancer, ‘NS_strict’ SNPs
 IQCA1 4.6 × 10–4 1 0 3.09 3
 PDE4A 1.2 × 10–3 1 1 0.53 2
 ECT2L 2.0 × 10–3 1 0 1.33 2
 GCKR 2.5 × 10–3 1 1 0.21 4
 ACSF3 2.6 × 10–3 1 1 0.17 3
ER+ breast cancer, ‘NS_all’ SNPs
 RTN4RL1 1.8 × 10–5 0.25 1 4.37 10
 OR2W5 7.3 × 10–5 1 1 16.16 11
 CYSRT1 1.0 × 10–4 1 1 0.23 2
 RNF130 1.3 × 10–4 1 0 0.69 3
 GABPA 1.3 × 10–4 1 1 0.02 2
ER+ breast cancer, ‘NS_broad’ SNPs
 RTN4RL1 3.2 × 10–5 0.39 1 2.00 6
 RNF130 1.3 × 10–4 1 0 0.69 3
 GABPA 1.3 × 10–4 1 1 0.02 2
 OR5H15 3.5 × 10–4 1 1 0.05 2
 TCHP 3.9 × 10–4 1 1 4.35 11
ER+ breast cancer, ‘NS_strict’ SNPs
 FSCN3 2.3 × 10–4 0.67 1 0.06 3
 GUF1 7.0 × 10–4 1 0 0.22 3
 ZIM3 7.8 × 10–4 1 1 0.87 2
 TSC2 8.0 × 10–4 1 0 0.61 5
 TBPL2 9.1 × 10–4 1 0 0.09 2
ER− breast cancer, ‘NS_all’ SNPs
 PDE4D 1.2 × 10–6 0.017 1 0.02 2
 PLEKHG5 2.2 × 10–5 0.31 1 9.36 18
 CCNDBP1 4.4 × 10–5 0.64 0 0.06 3
 DIMT1 5.8 × 10–5 0.84 0 0.03 2
 TEX12 1.6 × 10–4 1 0 0.20 2
ER− breast cancer, ‘NS_broad’ SNPs
 PDE4D 1.2 × 10–6 0.015 1 0.02 2
 LRRC8D 1.8 × 10–5 0.22 0 0.26 3
 CCNDBP1 4.4 × 10–5 0.54 0 0.06 3
 MRPS31 9.8 × 10–5 1 1 1.12 2
 NCR1 1.1 × 10–4 1 0 0.50 2
ER− breast cancer, ‘NS_strict’ SNPs
 FBXL22 8.2 × 10–6 0.023 1 0.02 2
 CCNDBP1 3.8 × 10–5 0.11 0 0.05 2
 SCARB1 9.6 × 10–5 0.28 1 0.02 2
 QRSL1 9.8 × 10–5 0.28 0 0.07 2
 MFGE8 1.1 × 10–4 0.31 0 0.05 3
MAF, minor allele frequency.aBonferroni correction for the number of genes tested.
bThe rho parameter indicates whether the SKAT test (rho = 0) or burden test (rho = 1) gave the smallest P value.
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FBXL22/ER− association in this study met strict criteria for vari-
ant functionality: these nonsynonymous SNPs were predicted to 
be damaging by five different algorithms (41–44).
Single SNP analyses confirmed an ER− association for the 
GWAS locus on chromosome 19p13.11 (12,52–56). The asso-
ciated SNP in the present study was the common missense 
variant rs8100241 in the ANKLE1 gene. This SNP has shown 
significant associations with overall (52), ER− (55) and triple-
negative (53) breast cancer in prior studies of mostly European 
ancestry subjects. These studies reported odds ratios rang-
ing from 0.84 to 0.88 for the A allele at this SNP, as compared 
with the odds ratio of 0.75 reported in the present analysis for 
ER− breast cancer. It should be noted, however, that the large 
GAME-ON meta-analysis (http://gameon.dfci.harvard.edu) 
reported weaker effect estimates for rs8100241: the odds ratio 
reported for overall breast cancer was 0.95 (95% CI 0.92, 0.99; 
P  =  0.017), and the odds ratio for ER− breast cancer was 0.94 
(95% CI 0.83, 1.07; P = 0.36).
Although the present study sample is the largest exome 
wide analysis sample to date for AA breast cancer, this analysis 
was underpowered to detect per-allele odds ratios <1.5, except 
when cumulative risk allele frequencies per gene approached 
or exceeded 5%. Further power limitations existed for analyses 
by ER status.
The significant gene-level findings reported here are based 
on four SNP variants that appear only once each in the AMBER 
sample of ER− cases and controls. Given these very small counts 
and the inflation seen in the gene-based test statistics, our 
results should be interpreted with caution. A  simple Fisher’s 
exact test for the presence of a rare allele in PDE4D versus ER− 
case/control status yields a P-value of 0.036, as does the same 
test for FBXL22. Fisher’s exact test is conservative and does not 
upweight rarer variants or account for covariates; however, the 
modest P value from this test emphasizes the need for replica-
tion to verify associations between these genes and ER− breast 
cancer.
This is not to say that the rare variant calls for the four SNPs 
of interest are questionable. There is good reason to believe that 
these calls were accurate in our study. These SNPs are known 
rare variants that the exome chip was designed to capture. 
Each SNP was seen in two or more studies that contributed 
sequence data for development of the exome chip: the minor 
allele at rs201360779 was seen 29 times across the ~12 000 
sequenced individuals, the minor allele at rs149590841 was seen 
seven times, and the minor alleles for the other two SNPs were 
each seen three times (ftp://share.sph.umich.edu/exomeChip/
ProposedContent/codingContent/). In AMBER, all four SNPs 
showed high quality genotype clusters and clear separation of 
the heterozygous calls from the remainder of the genotypes. In 
addition, SNP rs201360779 was not a true singleton in AMBER, 
having also been seen in one ER+ case.
The exome chip used here has inherent limitations. First and 
most obvious, this array-based method includes only selected 
rare variants and is therefore not as exhaustive as exome 
sequencing in capturing rare exonic variants. Second, this chip 
does not attempt to assay rare variation in noncoding regions. 
Third, the chip was designed using exome sequencing data 
from mostly European samples. Therefore, rare variants in non-
Europeans are not as well captured, and our data set may have 
lacked information on some important rare SNPs in AA popula-
tions (22).
Another potential limitation of our study is a current limi-
tation of the field: the use of traditional methods such as PCA 
(or linear mixed models) to adjust for population stratification Ta
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in rare variant association studies. These methods may not 
adequately control for population structure in some rare vari-
ant analysis settings; thus, the development of new methods for 
this purpose is an area of active research (23).
We should also acknowledge that while our multiple test-
ing correction adjusted for the number of genes analyzed, there 
were additional levels of testing that were not included in this 
correction. Multiple outcomes (overall, ER+, ER− breast cancer) 
and SNP functional groups (NS_all, NS_broad, NS_strict) were 
also analyzed. We did not correct for the multiple breast cancer 
outcomes because there was considerable overlap among the 
groups of patients analyzed for overall, ER+ and ER− breast can-
cer, and we considered these to be tests of related hypotheses. 
There was also a high amount of interdependence among the 
three SNP functional groups, which would render a Bonferroni 
correction overly conservative. Nevertheless, implementing an 
adjustment for all of the ER− gene-based tests conducted across 
the three SNP functional groups results in a corrected P value 
of 0.035 for PDE4D, although the corrected P value for FBXL22 
becomes non-significant (0.240).
In summary, an exome-wide gene-based analysis of rare 
variants found significant associations between the PDE4D and 
FBXL22 genes and ER− breast cancer in a collaborative study 
of AA women. The previous GWAS finding of a breast can-
cer risk marker in the PDE4D gene supports the idea that rare 
variants in this region in particular might affect breast cancer 
risk. Replication is needed to confirm the gene-level associa-
tions reported here, which are based on very small counts at 
extremely rare variants.
Supplementary material
Supplementary Tables 1–3 and Figures 1 and 2 can be found at 
http://carcin.oxfordjournals.org/.
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